{
  "nctId": "NCT02376790",
  "briefTitle": "Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis",
  "officialTitle": "A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis",
  "protocolDocument": {
    "nctId": "NCT02376790",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2016-08-31",
    "uploadDate": "2019-01-08T07:25",
    "size": 1763760,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02376790/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 851,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-03-03",
    "completionDate": "2018-07-06",
    "primaryCompletionDate": "2018-01-09",
    "firstSubmitDate": "2015-01-28",
    "firstPostDate": "2015-03-03"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria.\n* Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.\n* Subject has an active psoriatic skin lesion\n* Subject is naïve to etanercept and any other biologic for the treatment for PsA or psoriasis.\n* Subject has no prior use of methotrexate for PsA.\n* Subject has no history of tuberculosis\n* Subject has a negative test for tuberculosis, hepatitis B and C.\n\nExclusion Criteria:\n\n* Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.\n* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to the first dose of investigational product.\n* Subject has a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first dose of investigational product.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24",
        "description": "A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 20% improvement in 68 tender joint count;\n* ≥ 20% improvement in 66 swollen joint count; and\n* ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of joint pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein concentration.",
        "timeFrame": "Baseline and week 24"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants With a Minimal Disease Activity (MDA) Response at Week 24",
        "description": "Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:\n\n* Tender joint count (0-68) ≤ 1\n* Swollen joint count (0-66) ≤ 1\n* Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%\n* Patient global assessment of joint pain VAS (0-100) ≤ 15\n* Patient global assessment of disease activity VAS (0-100) ≤ 20\n* HAQ-DI (0-3) ≤ 0.5\n* Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time",
        "description": "A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 20% improvement in 68 tender joint count;\n* ≥ 20% improvement in 66 swollen joint count; and\n* ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of joint pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Over Time",
        "description": "A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 50% improvement in 68 tender joint count;\n* ≥ 50% improvement in 66 swollen joint count; and\n* ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of joint pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Over Time",
        "description": "A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:\n\n* ≥ 70% improvement in 68 tender joint count;\n* ≥ 70% improvement in 66 swollen joint count; and\n* ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of joint pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-reactive protein.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Tender Joint Count Over Time",
        "description": "The tender joint count is an assessment of the pain and/or tenderness of 68 joints using a 0 to 1 point scale (0 = none, 1 = present). The total tender joint count is calculated by summing the number of joints with present tenderness.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Swollen Joint Count Over Time",
        "description": "The swollen joint count is an assessment of the swelling of 66 joints using a 0 to 1 point scale (0 = none, 1 = present). The total swollen joint count is calculated by summing the number of joints with present swelling.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Physician Global Assessment of Disease Activity Over Time",
        "description": "A global assessment of the participant's arthritis assessed by the physician on a 100 mm visual analog scale (VAS) where 0 mm = No activity at all and 100 mm = Worst activity imaginable.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Patient Global Assessment of Disease Activity Over Time",
        "description": "A global assessment of the participant's arthritis, assessed by the participant on a 100 mm VAS where 0 mm = No arthritis activity at all and 100 mm = Worst arthritis activity imaginable.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Patient Global Assessment of Joint Pain Over Time",
        "description": "A global assessment of the severity of the participant's joint pain, assessed by the participant on a 100 mm VAS where 0 mm = No pain at all and 100 mm = Worst pain imaginable.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Over Time",
        "description": "The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in C-reactive Protein Concentration Over Time",
        "description": "C-reactive protein (CRP) is a specific measure of inflammatory activity.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Percentage of Participants With a American Minimal Disease Activity (MDA) Response Over Time",
        "description": "Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:\n\n* Tender joint count (0-68) ≤ 1\n* Swollen joint count (0-66) ≤ 1\n* Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%\n* Patient global assessment of joint pain VAS (0-100) ≤ 15\n* Patient global assessment of disease activity VAS (0-100) ≤ 20\n* HAQ-DI (0-3) ≤ 0.5\n* Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1",
        "timeFrame": "Weeks 4, 8, 12, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) Over Time",
        "description": "PASDAS is a measure of disease activity derived from the following variables:\n\n* Physician and patient global assessment of disease activity (assessed on a 0-100 VAS)\n* 68 tender joint count\n* 66 swollen joint count\n* Short Form-36 Questionnaire (SF-36) physical component summary (general health status on a scale from 0-100)\n* Tender dactylitis count (each digit assessed for tender dactylitis; total score 0-20)\n* Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6)\n* CRP level (mg/L)\n\nThe composite score is a weighted index where higher scores indicate more severe disease.",
        "timeFrame": "Baseline and weeks 12, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time",
        "description": "The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the following items:\n\n* 28 tender joint count,\n* 28 swollen joint count,\n* Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;\n* Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.\n\nThe CDAI score ranges from 0-76 where lower scores indicate less disease activity.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Simplified Disease Activity Index (SDAI) Over Time",
        "description": "The Simplified Disease Activity Index (SDAI) is a composite index that is calculated as the sum of the following items:\n\n* 28 tender joint count,\n* 28 swollen joint count,\n* Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;\n* Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.\n* CRP\n\nThe SDAI score ranges from 0 to 86 with higher scores representing worse disease.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in the Disease Activity Score 28 (DAS28) Over Time",
        "description": "The DAS28 measures the severity of disease at a specific time and is derived from the following variables:\n\n* 28 tender joint count\n* 28 swollen joint count\n* C-reactive protein (CRP)\n* Patient's global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.\n\nDAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.",
        "timeFrame": "Baseline and weeks 4, 8, 12, 16, 24, 36, and 48"
      },
      {
        "measure": "Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24",
        "description": "The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring in 8 functional areas: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Change From Baseline in Medical Outcomes Health Survey Short Form 36 Items Version 2 (SF-36 v2) at Week 24",
        "description": "The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains. Two summary component scores are calculated: mental component summary score (MCS) and physical component summary score (PCS). The MCS consists of social functioning, vitality, mental health, and role-emotional scales and the PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Week 24",
        "description": "The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:\n\n* pitting (scores 0-3, depending on the number of pits)\n* nail plate crumbling (scores 0-3, depending on the % of nail involvement)\n* onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)\n* leukonychia (0 = absent, 1 = present)\n* red spots in lunula (0 = absent, 1 = present)\n* nail bed hyperkeratosis (0 = absent, 1 = present)\n* splinter hemorrhages (0 = absent, 1 = present)\n\nIn participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.\n\nmNAPSI scores range from 0-13 where higher scores represent worse nail disease.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percentage of Participants With Clear mNAPSI at Week 24",
        "description": "The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:\n\n* pitting (scores 0-3, depending on the number of pits)\n* nail plate crumbling (scores 0-3, depending on the % of nail involvement)\n* onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)\n* leukonychia (0 = absent, 1 = present)\n* red spots in lunula (0 = absent, 1 = present)\n* nail bed hyperkeratosis (0 = absent, 1 = present)\n* splinter hemorrhages (0 = absent, 1 = present)\n\nIn participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.\n\nmNAPSI scores range from 0-13 where higher scores represent worse nail disease. Clear mNAPSI is defined as a score = 0.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Change From Baseline in Leeds Dactylitis Index (LDI) at Week 24",
        "description": "The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 \\[none\\] to 3 \\[worst\\]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percentage of Participants With Clear LDI at Week 24",
        "description": "The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 \\[none\\] to 3 \\[worst\\]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.\n\nClear LDI is defined as a score = 0.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Week 24",
        "description": "The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percentage of Participants With Clear SPARCC Enthesitis Index Score at Week 24",
        "description": "The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.\n\nClear SPARCC enthesitis is defined as a score = 0.",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis at Week 24",
        "description": "The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.\n\nPercent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline \\* 100",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis by Baseline BSA Involvement Subgroups",
        "description": "The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.\n\nPercent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline \\* 100",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Static Physician Global Assessment (sPGA) at Week 24",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Static Physician Global Assessment (sPGA) at Week 24 by Baseline BSA Involvement Subgroups",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Mean Static Physician Global Assessment (sPGA) Score at Week 24",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Mean Static Physician Global Assessment (sPGA) Score at Week 24 by Baseline BSA Involvement Subgroups",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24 by Baseline BSA Involvement Subgroups",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Baseline and week 24"
      },
      {
        "measure": "Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups",
        "description": "The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:\n\n0 = clear (no evidence of plaque elevation, erythema or scaling)\n\n1. = almost clear (minimal plaque elevation, erythema or scaling)\n2. = mild (mild plaque elevation or scaling, light red coloration)\n3. = moderate (moderate plaque elevation, scaling, light red coloration)\n4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)\n5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).",
        "timeFrame": "Baseline and week 24"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 36,
      "otherCount": 0,
      "totalCount": 37
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:57.165Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}